Contineum Therapeutics CEO Carmine N. Stengone disposes of 2,500 common shares for $41,141.5

• Contineum Therapeutics CEO and President Carmine N. Stengone sold 2,500 Class A common shares at USD 16.46 on Sep. 8, 2026.
• He acquired 2,500 Class A common shares at USD 1.01 via option exercise on the same day.
• Direct Class A common share holdings fell to 17,217 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-060962), on September 08, 2026, and is solely responsible for the information contained therein.